Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2013 3
2014 16
2015 8
2016 8
2017 4
2018 8
2019 3
2020 5
2021 17
2022 24
2023 24
2024 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Yang JC, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Passaro A, Kim SW, Gadgeel SM, Xie J, Sun T, Martinez M, Ennis M, Fennema E, Daksh M, Millington D, Leconte I, Iwasawa R, Lorenzini P, Baig M, Shah S, Bauml JM, Shreeve SM, Sethi S, Knoblauch RE, Hayashi H; MARIPOSA Investigators. Cho BC, et al. Among authors: yazici o. N Engl J Med. 2024 Oct 24;391(16):1486-1498. doi: 10.1056/NEJMoa2403614. Epub 2024 Jun 26. N Engl J Med. 2024. PMID: 38924756 Clinical Trial.
Bone marrow involvement in breast cancer.
Sütcüoğlu O, Özdemir N, Yazıcı O, Özet A. Sütcüoğlu O, et al. Among authors: yazici o. Curr Probl Cancer. 2022 Feb;46(1):100785. doi: 10.1016/j.currproblcancer.2021.100785. Epub 2021 Aug 15. Curr Probl Cancer. 2022. PMID: 34417058 No abstract available.
Thirty-day mortality rates after immunotherapy initiation.
Sütcüoğlu O, İlhan A, Tacar SY, Güven DC, Uçar G, Karadurmuş N, Yıldız F, Eraslan E, Uncu D, Tural D, Üner A, Günel N, Özdemir N, Kılıçkap S, Öksüzoğlu ÖB, Özet A, Yazıcı O. Sütcüoğlu O, et al. Among authors: yazici o. Immunotherapy. 2021 Dec;13(17):1419-1426. doi: 10.2217/imt-2021-0082. Epub 2021 Oct 22. Immunotherapy. 2021. PMID: 34676791
Brigatinib-induced tuberculosis reactivation: A case report.
Keş V, Sütcüoğlu O, Gürler F, Yazıcı O, Özet A. Keş V, et al. Among authors: yazici o. Curr Probl Cancer. 2021 Dec;45(6):100738. doi: 10.1016/j.currproblcancer.2021.100738. Epub 2021 Apr 10. Curr Probl Cancer. 2021. PMID: 33867154
Niraparib-induced pure red cell aplasia.
Bir Yücel K, Yıldız S, Sütcüoglu O, Güvercin FS, Uyar Göçün P, Özdemir N, Yazıcı O, Özet A. Bir Yücel K, et al. Among authors: yazici o. J Oncol Pharm Pract. 2024 Jan;30(1):210-214. doi: 10.1177/10781552231197808. Epub 2023 Aug 29. J Oncol Pharm Pract. 2024. PMID: 37642988
Combination therapies in non-clear-cell renal cell carcinoma.
Aslan V, Özdemir N, Yazıcı O, Özet A. Aslan V, et al. Among authors: yazici o. Lancet Oncol. 2023 Oct;24(10):e401. doi: 10.1016/S1470-2045(23)00393-5. Lancet Oncol. 2023. PMID: 37797639 No abstract available.
ROAR trial: which treatment is effective after progression?
Sütcüoğlu O, Yücel KB, Üner A, Yazici O, Özdemir N. Sütcüoğlu O, et al. Among authors: yazici o. Lancet Oncol. 2022 Mar;23(3):e93. doi: 10.1016/S1470-2045(21)00754-3. Lancet Oncol. 2022. PMID: 35240094 No abstract available.
119 results